Logo image of ONCT

Oncternal Therapeutics Inc (ONCT) Stock Fundamental Analysis

NASDAQ:ONCT - Nasdaq - US68236P2065 - Common Stock - Currency: USD

0.5266  -0.17 (-24.11%)

After market: 0.61 +0.08 (+15.84%)

Fundamental Rating

2

ONCT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. The financial health of ONCT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ONCT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ONCT has reported negative net income.
ONCT had a negative operating cash flow in the past year.
ONCT had negative earnings in each of the past 5 years.
ONCT had a negative operating cash flow in each of the past 5 years.
ONCT Yearly Net Income VS EBIT VS OCF VS FCFONCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

ONCT's Return On Assets of -221.62% is on the low side compared to the rest of the industry. ONCT is outperformed by 91.70% of its industry peers.
ONCT has a worse Return On Equity (-377.95%) than 77.39% of its industry peers.
Industry RankSector Rank
ROA -221.62%
ROE -377.95%
ROIC N/A
ROA(3y)-68.44%
ROA(5y)-75.41%
ROE(3y)-79.79%
ROE(5y)-98.7%
ROIC(3y)N/A
ROIC(5y)N/A
ONCT Yearly ROA, ROE, ROICONCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

ONCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCT Yearly Profit, Operating, Gross MarginsONCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ONCT has been increased compared to 1 year ago.
Compared to 5 years ago, ONCT has more shares outstanding
There is no outstanding debt for ONCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ONCT Yearly Shares OutstandingONCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
ONCT Yearly Total Debt VS Total AssetsONCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

ONCT has an Altman-Z score of -26.66. This is a bad value and indicates that ONCT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -26.66, ONCT is not doing good in the industry: 90.11% of the companies in the same industry are doing better.
There is no outstanding debt for ONCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.66
ROIC/WACCN/A
WACCN/A
ONCT Yearly LT Debt VS Equity VS FCFONCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 2.39 indicates that ONCT has no problem at all paying its short term obligations.
With a Current ratio value of 2.39, ONCT is not doing good in the industry: 71.73% of the companies in the same industry are doing better.
ONCT has a Quick Ratio of 2.39. This indicates that ONCT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ONCT (2.39) is worse than 70.32% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.39
ONCT Yearly Current Assets VS Current LiabilitesONCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.82% over the past year.
The Revenue has grown by 227.92% in the past year. This is a very strong growth!
ONCT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -38.50% yearly.
EPS 1Y (TTM)18.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.88%
Revenue 1Y (TTM)227.92%
Revenue growth 3Y-38.5%
Revenue growth 5YN/A
Sales Q2Q%175.98%

3.2 Future

The Earnings Per Share is expected to grow by 9.92% on average over the next years. This is quite good.
The Revenue is expected to grow by 3.60% on average over the next years.
EPS Next Y10.27%
EPS Next 2Y10.73%
EPS Next 3Y15.35%
EPS Next 5Y9.92%
Revenue Next Year161.75%
Revenue Next 2Y-2.29%
Revenue Next 3Y16.74%
Revenue Next 5Y3.6%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ONCT Yearly Revenue VS EstimatesONCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1M 2M 3M 4M
ONCT Yearly EPS VS EstimatesONCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ONCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCT Price Earnings VS Forward Price EarningsONCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCT Per share dataONCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as ONCT's earnings are expected to grow with 15.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.73%
EPS Next 3Y15.35%

More info and screens

0

5. Dividend

5.1 Amount

ONCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Oncternal Therapeutics Inc

NASDAQ:ONCT (12/2/2024, 8:00:01 PM)

After market: 0.61 +0.08 (+15.84%)

0.5266

-0.17 (-24.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners12.07%
Inst Owner Change-11.17%
Ins Owners155.35%
Ins Owner Change0%
Market Cap1.56M
Analysts43.33
Price Target2.04 (287.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.49%
Min EPS beat(2)8.75%
Max EPS beat(2)12.24%
EPS beat(4)4
Avg EPS beat(4)6.29%
Min EPS beat(4)0.6%
Max EPS beat(4)12.24%
EPS beat(8)7
Avg EPS beat(8)3.47%
EPS beat(12)11
Avg EPS beat(12)6.79%
EPS beat(16)12
Avg EPS beat(16)5.27%
Revenue beat(2)2
Avg Revenue beat(2)241.44%
Min Revenue beat(2)230.65%
Max Revenue beat(2)252.23%
Revenue beat(4)4
Avg Revenue beat(4)202.6%
Min Revenue beat(4)111.77%
Max Revenue beat(4)252.23%
Revenue beat(8)6
Avg Revenue beat(8)96.43%
Revenue beat(12)8
Avg Revenue beat(12)59.15%
Revenue beat(16)10
Avg Revenue beat(16)55.05%
PT rev (1m)-90.24%
PT rev (3m)-92.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.44%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-11.69
EYN/A
EPS(NY)-10.45
Fwd EYN/A
FCF(TTM)-9
FCFYN/A
OCF(TTM)-9
OCFYN/A
SpS0.73
BVpS3.09
TBVpS3.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -221.62%
ROE -377.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-68.44%
ROA(5y)-75.41%
ROE(3y)-79.79%
ROE(5y)-98.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 2.39
Altman-Z -26.66
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.88%
EPS Next Y10.27%
EPS Next 2Y10.73%
EPS Next 3Y15.35%
EPS Next 5Y9.92%
Revenue 1Y (TTM)227.92%
Revenue growth 3Y-38.5%
Revenue growth 5YN/A
Sales Q2Q%175.98%
Revenue Next Year161.75%
Revenue Next 2Y-2.29%
Revenue Next 3Y16.74%
Revenue Next 5Y3.6%
EBIT growth 1Y18.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.4%
OCF growth 3YN/A
OCF growth 5YN/A